These findings suggest that sPD-1 and sPD-L1 levels may reflect distinct biological and clinical characteristics in bone tumors, with sPD-1 more strongly associated with patient demographics and disease progression, while sPD-L1 appears to be primarily influenced by tumor differentiation. Here, HOXD13 is linked to neoplasm.